KaydedilenlerDerginizi ekleyin

Dergiler / Eurasian Journal of Medical Investigation / 2022 / Cilt: 6 - Sayı: 2

Impact of Breast Cancer Subtypes on Pathological Complete Response Following Neoadjuvant Chemotherapy

Melike ÖZÇELİK
İbrahim ÇİL
Abdilkerim OYMAN
Sayfa
147–150
Yayın Tarihi
2022-10-12
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

In the evaluation of the factors affecting the pathological complete response, statistical significance was obtained in progesterone receptor status and breast cancer subtypes in the multivariate analysis (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objectives: We aimed to identify the clinicopathological characteristics associated with pathological complete response (pCR) following neoadjuvant chemotherapy in breast cancer.
📊
Temel Bulgular & Veri:Methods: Between 2009 and 2020, 105 female patients diagnosed with non-metastatic, T1-4, N1-3 breast cancer, undergoing neoadjuvant therapy followed by surgery and then radiotherapy were included in the study.
💡
Sonuç & Katkı:In the evaluation of the factors affecting the pathological complete response, statistical significance was obtained in progesterone receptor status and breast cancer subtypes in the multivariate analysis (p
🔬Tür:Araştırma Makalesi
📍Kapsam:2009 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Objectives: We aimed to identify the clinicopathological characteristics associated with pathological complete response (pCR) following neoadjuvant chemotherapy in breast cancer. Methods: Between 2009 and 2020, 105 female patients diagnosed with non-metastatic, T1-4, N1-3 breast cancer, undergoing neoadjuvant therapy followed by surgery and then radiotherapy were included in the study. All patients received anthracycline and taxane-based treatments. Patients with Her-2 positivity received additional trastuzumab treatment. Results: A total of 105 female patients were included in the study. The median age was found to be 52 years. 50 (47.6%) patients were premenopausal and 55 (52.4%) patients were postmenopausal. Pathological complete response was obtained in 26 (24.7%) patients who received neoadjuvant therapy. In the evaluation of the factors affecting the pathological complete response, statistical significance was obtained in progesterone receptor status and breast cancer subtypes in the multivariate analysis (p

🔖

Bu Makaleye Atıf Yap

ÖZÇELİK, M., ÇİL, İ., OYMAN, A. (2022). Impact of Breast Cancer Subtypes on Pathological Complete Response Following Neoadjuvant Chemotherapy. Eurasian Journal of Medical Investigation, Cilt: 6 - Sayı: 2, 147–150. https://ajindex.com/articles/508514

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Fahad Ullah M. Breast cancer: current perspectives on the disease status. Adv Exp Med Biol 2019;1152:51–64
  2. Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 2005;97:188–94
  3. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenberg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778–85
  4. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747–52
  5. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492–502
  6. Broglio KR, Quintana M, Foster M, Olinger M, McGlothlin A, Berry SM, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-positive breast cancer with long-term outcomes: a meta-analysis. JAMA Oncol 2016;2:751–60
  7. Guarneri V, Broglio K, Kau SW, Cristofanilli M, Buzdar AU, Valero V, et al. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037–44
  8. Lv Y, Li Y, Mu W, Fu H. Factors affecting pathological complete response after neoadjuvant chemotherapy in operable primary breast cancer. J Coll Physicians Surg Pak 2020;30:389–93
  9. Andrade DA, Zucca-Matthes G, Vieira RA, Andrade CT, Costa AM, Monteiro AJ, et al. Neoadjuvant chemotherapy and pathologic response: a retrospective cohort. Einstein (Sao Paulo) 2013;11:446–50
  10. Houssami N, Macaskill P, von Minckwitz G, Marinovich ML, Mamounas E. Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. Eur J Cancer 2012;48:3342–54
  11. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329– 34
  12. Prat A, Fan C, Fernández A, Hoadley KA, Martinello R, Vidal M, et al. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy. BMC Med 2015;13:303.